StockWatch
·
NGL FINE-CHEM · Q2 FY27 · THE VERDICT

32% Growth, Margin Pressure Next — The Phase II Ramp Story

Q2 delivered 32% YoY revenue growth and 69% YoY PAT growth, hitting guidance squarely. But sequential PAT fell 11.7% QoQ despite 14% revenue growth — a gap that reveals the real quarter: strong demand is real, but new facility ramp pressure is biting margins, and working capital is eating cash.

Q2 FY27 resultsNGLFINENGL FINE-CHEM LTD.18 Nov 2026 · 6 min read

NGL Fine-Chem delivered a quarter that looks strong on the headline but tells a more nuanced story on the tape. Q2 FY27 revenue hit ₹158.7 Cr, up 32% YoY and 14% QoQ, with EBITDA at ₹28.1 Cr (17.7% margin) sitting squarely within management's 15%-18% guided range. PAT came in at ₹16.2 Cr, up 69% YoY. By any mark, this is a solid quarter that validates the demand recovery story post-inventory normalization. Management's confidence is audible — and the numbers back it.

But here's the tension

Q2 Revenue growth (QoQ)

+14%

sequential

Q2 PAT growth (QoQ)

-11.7%

sequential

PAT fell 11.7% QoQ (from ₹18.4 Cr in Q1 to ₹16.2 Cr in Q2) despite revenue climbing 14%. That's the story. The gap isn't a one-time item — it's structural. Phase II facility depreciation has started (~₹3 Cr more ahead), inventory carrying costs remain elevated (₹118.4 Cr in September, up from ₹70.3 Cr in March), and fuel and logistics costs have nearly doubled from Gulf War disruptions. At 30%-40% facility utilization (the target for the next 2-3 quarters), fixed costs cannot be fully absorbed yet. Margins are compressing, not because demand is soft, but because the company is in the middle of a costly ramp.

Claims vs. what holds up

  • Q2 revenue ₹158.7 Cr, 32% YoY growth matches and exceeds prior ₹150 Cr run-rate target

  • EBITDA margin 17.7% within guided 15%-18% range; 64% YoY EBITDA growth on volume

  • Growth driven by volumes, not price — analyst-verified on the call; substantial part from volumes

  • Phase II facility operational (Sep 2026) and staffed; concrete utilization ramp to 30%-40% planned

  • No pricing power visible; Fluralaner prices down, stability expected only in 6+ months

  • Sequential PAT decline despite QoQ revenue growth flags real near-term margin pressure

What changed on this call

Phase II facility now live. The ₹220+ Cr greenfield Tarapur facility was commissioned in September 2026 and is now in production ramp. This is a step-change in the company's footprint — but it comes with depreciation drag (~₹3 Cr annually) and absorbs management's strategic focus for the next 2-3 quarters as utilization climbs from low teens to 30%-40%.

Inventory strategy shifted from just-in-time to manufacturing-to-stock. The jump from ₹70.3 Cr (March 2026) to ₹118.4 Cr (September 2026) reflects a deliberate pivot — the company is building stock for expected demand ramp and hedging against supply-chain shocks (Gulf War fears). Working capital is tighter as a result, and management flagged it as a 'priority' moving forward. Expect normalization over 2-3 quarters as Phase II ramps and demand stabilizes.

Europe timeline extended. Prior guidance hinted at ₹50-60 Cr from Europe 'this year.' That target has been implicitly walked back. Management now guides critical mass to 2028-2030, with 9 of 17 regulatory filings approved to date and customer onboarding taking 2-3 years post-approval. This is realistic but represents a markdown on near-term upside.

Margins reaffirmed, not upgraded. Despite 32% YoY revenue growth and near-term operational leverage from Phase II, management held the 15%-18% long-term EBITDA margin guidance unchanged. That restraint tells you something: the company expects the cost base to rise in line with or above revenue during this facility ramp phase. It's prudent, but it's also a signal that near-term margin expansion is not in the cards.

How the street sees it

NGL's stock closed at ₹2,859.9 on the day of this analysis (Nov 18, 2026), trading above all major moving averages — SMA20 (₹2,758.84), SMA50 (₹2,801.92), and SMA200 (₹2,675.75). That's a bullish technical setup. RSI at 52 sits in neutral territory, suggesting neither overbought nor oversold conditions. Volume has remained normal — no panic sellers, no frenzied buyers. The stock is -20.6% from its all-time high of ₹3,602, which provides a backdrop: the market had priced in more near-term upside than has materialized, and the drawdown offers context for the current price. Off its 52-week low of ₹1,271, the stock is +125%, reflecting the genuine recovery arc.

Institutionally, ownership remains heavily concentrated: promoters hold 72.49%, while FII and DII are virtually absent (0.04% and 0.00% respectively as of Q2 FY27). This is not a stock driven by institutional flows. That can be an advantage in a retail-led market, but it also means the equity story travels more on fundamentals than on passive inflows. No net change in FII/DII from prior quarters signals muted institutional interest in the near term.

The bull-bear ledger

  • 32% YoY revenue growth, 69% YoY PAT growth validates demand recovery post-inventory depletion cycle

  • Beat prior ₹150 Cr quarterly run-rate target; now stabilized at ₹158+ Cr

  • EBITDA margin 17.7% within 15%-18% guided range; demonstrates pricing + cost discipline mid-ramp

  • Phase II facility now operational with concrete 2-3 quarter utilization ramp to 30%-40%

  • Long-term regulated market upside (Europe/US) intact; 9 of 17 EU filings approved; 9 US veterinary master files filed

  • H1 FY27 operating cash flow ₹35.8 Cr demonstrates ability to fund growth

  • Sequential PAT decline (-11.7% QoQ on +14% revenue) reveals real margin compression, not headline illusion

  • Inventory spike (₹70.3 Cr → ₹118.4 Cr) creates working capital drain; normalization timing uncertain

  • Phase II depreciation (~₹3 Cr more ahead) will continue to pressure near-term earnings

  • No pricing power visible despite demand recovery; Fluralaner pricing down, stability 6+ months away

  • Europe/US catalysts deferred to 2028-2030; near-term revenue concentration remains unregulated market

  • Top 10 customers = 26% of sales; top 10 products = 65% of revenue — concentration risk material

  • Net debt ₹122 Cr (up from ₹108 Cr prior year); capex intensity masks leverage build

Risks ranked by concern to a holder

What could derail the story — ordered by severity for shareholders

Margin compression persists beyond 2-3 quarters as Phase II ramps slowly

HIGH

If Phase II utilization lags expectations (stuck below 30%) or new customers fail to ramp, depreciation drag (~₹3 Cr annually + ₹1-2 Cr finance cost increases) will not be absorbed and EBITDA margins could slip below 15%. Sequential PAT decline is a warning signal.

US regulatory approval delayed or flagged on first FDA audit

HIGH

9 US veterinary master files filed; customer filing expected Dec 2026. First-time FDA audit could uncover observations that delay approval 6-12 months. This is a binary catalyst risk in the 3-12 month window.

Working capital spiral if inventory doesn't normalize or demand weakens

MEDIUM

₹118.4 Cr inventory vs. ₹70.3 Cr prior is a ₹48+ Cr cash drag. If sales don't scale to absorb this or demand weakens, cash conversion could deteriorate. Net debt already ₹122 Cr (up from ₹108 Cr); capex still ongoing.

Customer or product concentration loss

MEDIUM

Loss of a top-10 customer (26% of sales) or a top-10 product (65% of revenue) would be material. Unregulated market is concentrated; customer moat is execution and cost, not IP.

Commodity/logistics costs don't normalize; geopolitical risk persists

LOW

Transportation costs nearly doubled from Gulf War. If tensions persist, margins stay compressed. But management expects normalization as the situation improves; limited upside if inflation proves sticky.

The debate

The honest read: NGL is in a transitional quarter — strong demand is real, growth is organic, but hidden margin pressure from new facility ramp is biting near-term earnings. The company is not over-promising (margins held, not raised), which is credible. But the sequential PAT decline is a yellow flag: the ramp will eat near-term earnings before it delivers leverage. This is a "prove it" moment. The question is not whether Phase II will eventually accrete value — the facility is live and will — but whether the market will tolerate 2-3 quarters of margin compression while utilization climbs to 30%-40%. At ₹2,859.9, the stock is fairly valued but not compelling enough to compensate for near-term earnings visibility risk.

What to watch next

Four catalysts to track over the next 2-3 quarters
  • 1 · Q3 and Q4 FY27: Inventory normalization and working capital easing

    Watch whether ₹118.4 Cr inventory starts to normalize. Mgmt expects this over 2-3 qtrs as Phase II ramps and demand absorbs stock. If inventory remains elevated or grows further, working capital pressure persists and cash flow deteriorates.

  • 2 · December 2026: US customer filings and FDA inspection timeline

    9 US veterinary master files have been filed; customer is expected to trigger their filing by December 2026. First-time audit timeline is 3-12 months. Any flag or delay here would push US revenue into 2027-28, extending the near-term revenue concentration in unregulated markets.

  • 3 · Q4 FY27 to Q1 FY28: Phase II utilization ramp and fixed cost absorption

    Watch whether Phase II utilization climbs to 30%-40% as planned and whether fixed cost absorption improves. If utilization lags or new customers fail to ramp, depreciation drag will persist and margin compression will extend beyond 3 quarters.

  • 4 · End-2027: Europe regulatory approvals and customer onboarding

    9 of 17 EU filings have been approved. Target is all 17 by end-2027. Customer onboarding takes 2-3 years post-approval. Any approval delays or slower-than-expected customer ramp would push critical mass into 2029-2030.

The number to track

From this point forward, the metric that will determine whether this story holds is adjusted EBITDA margin trend over the next 2-3 quarters. If it stays within or above 15% while utilization climbs to 30%-40% and inventory normalizes, the Phase II ramp is working and the near-term pain is worth the long-term gain. If it compresses below 15%, the fixed cost burden is higher than expected, and a downgrade to earnings growth (and multiple) would be warranted. Watch the guidance reaffirmation or revision in Q3 FY27 earnings — that will tell you whether management still believes in the 15%-18% range or is signaling a need for patience.

NGL Fine-Chem delivered a quarter that is fundamentally sound but tactically complex. Demand is real, growth is organic, and long-term upside (regulated markets, Phase II capacity) is intact. But the hidden story — sequential PAT decline despite revenue growth — reveals the near-term cost of that growth. This is a company in transition, not a misstep.

Rating: Hold. The stock is fairly valued at ₹2,859.9 but not compelling until Phase II utilization and margin normalization become visible in Q3-Q4 FY27. Near-term guidance holders should wait for Q3 confirmation that the margin story holds. Long-term builders who believe in the regulated-market thesis (Europe/US post-2028) should dollar-cost average in, but expect near-term volatility if margin pressure persists. The number to track: adjusted EBITDA margin. If it holds 15%+ as utilization ramps, hold. If it slips below 15%, reassess.

Informational and educational content only. Not investment advice.